Los Angeles, California
Cancer biologic therapy trials in Los Angeles, CA
73 cancer biologic therapy studies are recruiting participants at sites in Los Angeles as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Los Angeles at a glance
- 73 studies are recruiting at a site in Los Angeles.
- By phase: Phase 1 (11), Phase 1/2 (16), Phase 2 (17), Phase 2/3 (2), Phase 3 (26), Observational (1).
- By sponsor: industry (42), university, hospital or other (17), government (14).
- By research area: Lung Cancer (22), Lymphoma (19), Breast Cancer (18), Melanoma (8), Pancreatic Cancer (3), Prostate Cancer (3).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Los Angeles
Basic details from each study's public record (the 30 most recently updated of 73). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cedars-Sinai Medical Center · The Angeles Clinic and Research Institute - West Los Angeles Office
- Registry record
- NCT05564377 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047)
- Registry record
- NCT06841354 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cedars-Sinai Medical Center · The Angeles Clinic and Research Institute - West Los Angeles Office
- Registry record
- NCT06058377 · updated
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Immunomic Therapeutics, Inc.
- Study site
- The Angeles Clinic and Research Institute (TACRI)
- Registry record
- NCT07652242 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Los Angeles Hematology Oncology Medical Group ( Site 0026)
- Registry record
- NCT07060807 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.
Lung cancer studies recruiting in Los Angeles
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cedars-Sinai Medical Center
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cedars-Sinai Medical Center · Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles
- Registry record
- NCT07388524 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- UCLA Jonsson Comprehensive Cancer Center ( Site 0135) · USC Norris Comprehensive Cancer Center ( Site 0205)
- Registry record
- NCT06623422 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles
- Registry record
- NCT04267848 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033)
- Registry record
- NCT06312137 · updated
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07099898 · updated
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Obsidian Therapeutics, Inc.
- Study sites
- The Angeles Clinic and Research Institute (Melanoma) · USC Norris Comprehensive Cancer Center (Melanoma/NSCLC)
- Registry record
- NCT06060613 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Los Angeles
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Keck Medicine of USC Koreatown · Los Angeles General Medical Center · USC / Norris Comprehensive Cancer Center
- Registry record
- NCT03866382 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Cedars Sinai Medical Center · Ronald Reagan UCLA Medical Center
- Registry record
- NCT07164443 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study sites
- UCLA Department of Medicine · USC Norris Comprehensive Cancer Center
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.
Melanoma studies recruiting in Los Angeles
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cedars-Sinai Medical Center · Los Angeles General Medical Center · The Angeles Clinic and Research Institute - West Los Angeles Office
- Registry record
- NCT05136196 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- UCLA Hematology/Oncology
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Los Angeles, CA on ClinicalTrials.gov.
Lymphoma studies recruiting in Los Angeles
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cedars-Sinai Medical Center
- Registry record
- NCT06337318 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Children's Hospital Los Angeles
- Registry record
- NCT06173518 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Cedars-Sinai Medical Center ( Site 0115)
- Registry record
- NCT06717347 · updated
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Cedar Sinai Cancer Center ( Site 0119)
- Registry record
- NCT07519772 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cedars-Sinai Medical Center · Children's Hospital Los Angeles · Mattel Children's Hospital UCLA
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cedars-Sinai Medical Center · Children's Hospital Los Angeles
- Registry record
- NCT05675410 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cedars-Sinai Medical Center
- Registry record
- NCT06649812 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study sites
- Cedars-Sinai Medical Center · University of California, Los Angeles (UCLA)
- Registry record
- NCT07188558 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Cedars-Sinai Medical Center
- Registry record
- NCT05976763 · updated
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Phase 1/2
- From 6 months, up to 25 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Children's Hospital Los Angeles ( Site 1006)
- Registry record
- NCT06395103 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study sites
- Cedars-Sinai Medical Center · University of California, Los Angeles
- Registry record
- NCT06500273 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Los Angeles, CA on ClinicalTrials.gov.
Ask about studies near Los Angeles
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in California
All California locations
185 studies recruiting across 108 cities.
Duarte
77 studies recruiting.
San Francisco
37 studies recruiting.
Sacramento
36 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections